Lorcaserin: Drug profile and illustrative model of the regulatory challenges of weight-loss drug development

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 3, 2011, Pages 265-277

  Bays, Harold E ^a  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

Author keywords

'sick fat'; adiposopathy; dyslipidemia; FDA; lorcaserin; obesity; regulatory

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LORCASERIN; PLACEBO; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; TETRAHYDROLIPSTATIN;

ARTICLE; BACKACHE; BIOCHEMISTRY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BIOAVAILABILITY; ENERGY EXPENDITURE; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NAUSEA; NONHUMAN; OBESITY; OBSESSIVE COMPULSIVE DISORDER; PARKINSON DISEASE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RHINOPHARYNGITIS; SCHIZOPHRENIA; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; BENZAZEPINES; DRUG APPROVAL; DRUG DESIGN; HUMANS; OBESITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WEIGHT LOSS;

EID: 79953248782     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.22     Document Type: Article

References (53)

1. Bray GA. Medical consequences of obesity. J. Clin. Endocrinol. Metab. 89(6), 2583-2589 (2004). (Pubitemid 38766335)
2. Kushner RF, Roth JL. Assessment of the obese patient. Endocrinol. Metab. Clin. North Am. 32(4), 915-933 (2003). (Pubitemid 38029987)
3. Powers KA, Rehrig ST, Jones DB. Financial impact of obesity and bariatric surgery. Med. Clin. North Am. 91(3), 321-338, ix (2007). (Pubitemid 46726483)
4. Tsai AG, Wadden TA. Systematic review: An evaluation of major commercial weight loss programs in the United States. Ann. Intern. Med. 142(1), 56-66 (2005).
5. Bays HE. 'Sick fat,' metabolic disease, and atherosclerosis. Am. J. Med. 122(1 Suppl.), S26-S37 (2009).
6. Bays H, Abate N, Chandalia M. Adiposopathy: Sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiol. 1(1), 39-59 (2005).
7. Bays H, Ballantyne C. Adiposopathy: Why do adiposity and obesity cause metabolic disease? Future Lipidol. 1(4), 389-420 (2006).
8. Bays H, Blonde L, Rosenson R. Adiposopathy: How do diet, exercise, weight loss and drug therapies improve metabolic disease? Expert Rev. Cardiovasc. Ther. 4(6), 871-895 (2006). (Pubitemid 46017525)
9. Bays HE, Rodbard RW, Schorr AB, González-Campoy JM. Adiposopathy: Treating pathogenic adipose tissue to reduce cardiovascular disease risk. Curr. Treat. Options Cardiovasc. Med. 9(4), 259-271 (2007). (Pubitemid 47181092)
10. Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Expert Rev. Cardiovasc. Ther. 8(12), 1777-1807 (2010).
11. Bays HE, Gonzalez-Campoy JM, Bray GA et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev. Cardiovasc. Ther. 6(3), 343-368 (2008).
12. Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin. Drug Saf. 4(6), 1083-1095 (2005). (Pubitemid 41671605)
13. Bays H. Perspective: Is bias behind the lack of new obesity drug therapies? Clin. Endocrinol. News 5(8), 10 (2010).
14. Bays HE. Lorcaserin and adiposopathy: 5-HT2C agonism as a treatment for 'sick fat' and metabolic disease. Expert Rev. Cardiovasc. Ther. 7(11), 1429-1445 (2009).
15. Coleman E. FDA briefing document. NDA 22529 Lorqess (lorcaserin hydrochloride) Tablets, 10 mg Sponsor: Arena Pharmaceuticals Advisory Committee (2010).
16. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 17(3), 494-503 (2009).
17. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: A meta-analysis. Am. J. Clin. Nutr. 56(2), 320-328 (1992).
18. Smith SR, Weissman NJ, Anderson CM et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363(3), 245-256 (2010).
19. Smith SR, Weissman NJ, Stubbe S, Anderson CM, Shanahan WR. Lorcaserin reduces body weight in obese and overweight subjects: Behavioral modification and lorcaserin for overweight and obese management; the BLOOM Trial. Abstract Poster Presentation no. 96. Presented at: American Diabetes Association 69th Scientific Session. New Orleans, LA, USA, 5-9 June 2009.
20. Bays H. Adiposopathy: The endocannabinoid system as a therapeutic treatment target for dysfunctional 'sick' fat. CJHP 19(1), 32-39 (2007).
21. Fong TM, Heymsfield SB. Cannabinoid-1 receptor inverse agonists: Current understanding of mechanism of action and unanswered questions. Int. J. Obes. (Lond). 33(9), 947-955 (2009).
22. Topol EJ, Bousser MG, Fox KA et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): A randomised, multicentre, placebo-controlled trial. Lancet 376(9740), 517-523 (2010).
23. No authors listed. Rimonabant: Marketing authorization suspended⋯ at last: Withdrawal. Half-measures. Prescrire Int. 18(100), 61 (2009).
24. Rosenzweig-Lipson S, Dunlop J, Marquis KL. 5-HT2c receptor agonists as an innovative approach for psychiatric disorders. Drug News Perspect. 20(9), 565-571 (2007). (Pubitemid 351480207)
25. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories- IA and -II in psychiatric outpatients. J. Pers. Assess. 67(3), 588-597 (1996). (Pubitemid 26382973)
26. CDC. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb. Mortal. Wkly. Rep. 46, 1061-1066 (1997).
27. Contrera JF, Matthews EJ, Kruhlak NL, Benz RD. Estimating the safe starting dose in Phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. Regul. Toxicol. Pharmacol. 40(3), 185-206 (2004). (Pubitemid 39531301)
28. Wade JM, Juneja P, MacKay AW et al. Synergistic impairment of glucose homeostasis in ob/ob mice lacking functional serotonin 2c receptors. Endocrinology 149(3), 955-961 (2008). (Pubitemid 351397943)
29. Nonogaki K, Kaji T, Ohba Y, Sumii M, Wakameda M, Tamari T. Serotonin 5-HT2c receptor-independent expression of hypothalamic NOR1, a novel modulator of food intake and energy balance, in mice. Biochem. Biophys. Res. Commun. 386(2), 311-315 (2009).
30. Hayashi A, Sonoda R, Kimura Y et al. Antiobesity effect of YM348, a novel 5-HT2c receptor agonist, in Zucker rats. Brain Res. 1011(2), 221-227 (2004). (Pubitemid 38638688)
31. Thomsen WJ, Grottick AJ, Menzaghi F et al. Lorcaserin, a novel selective human 5-hydroxytryptamine 2c agonist: In vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther. 325(2), 577-587 (2008). (Pubitemid 351574813)
32. Gross L, Dreyfuss Y. Spontaneous tumors in Sprague-Dawley and Long-Evans rats and in their F1 hybrids: Carcinogenic effect of total-body x-irradiation. Proc. Natl Acad. Sci. USA 76(11), 5910-5913 (1979). (Pubitemid 10216686)
33. Cohen SM, Klaunig J, Meek ME et al. Evaluating the human relevance of chemically induced animal tumors. Toxicol. Sci. 78(2), 181-186 (2004). (Pubitemid 38559665)
34. Ghoshal A, Preisegger KH, Takayama S, Thorgeirsson SS, Snyderwine EG. Induction of mammary tumors in female Sprague-Dawley rats by the food-derived carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine and effect of dietary fat. Carcinogenesis 15(11), 2429-2433 (1994). (Pubitemid 24343670)
35. Welsch CW, Nagasawa H. Prolactin and murine mammary tumorigenesis: A review. Cancer Res. 37(4), 951-963 (1977). (Pubitemid 8088159)
36. Welsch CW, Nagasawa H, Meites J. Increased incidence of spontaneous mammary tumors in female rats with induced hypothalamic lesions. Cancer Res. 30(9), 2310-2313 (1970).
37. Bjerre Knudsen L, Madsen LW, Andersen S et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151(4), 1473-1486 (2010).
38. Soffritti M, Belpoggi F, Degli Esposti D et al. First experimental demonstration of the multipotential carcinogenic effects of aspartame administered in the feed to Sprague-Dawley rats. Environ. Health Perspect. 114(3), 379-385 (2006). (Pubitemid 43338263)
39. Yang Q. Gain weight by 'going diet?' Artificial sweeteners and the neurobiology of sugar cravings: Neuroscience 2010. Yale J. Biol. Med. 83(2), 101-108 (2010).
40. James WP, Caterson ID, Coutinho W et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 363(10), 905-917 (2010).
41. Sawbridge DT, Fitzgerald R. 'Lazy, slothful and indolent': Medical and social perceptions of obesity in Europe to the eighteenth century. Vesalius 15(2), 59-70 (2009).
42. Bluher M. Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diabetes 117(6), 241-250 (2009).
43. Bays HE, Gonzalez-Campoy JM, Henry RR et al. Is adiposopathy (sick fat) an endocrine disease? Int. J. Clin. Pract. 62(10), 1474-1483 (2008).
44. Kummar S, Rubinstein L, Kinders R et al. Phase 0 clinical trials: Conceptions and misconceptions. Cancer J. 14(3), 133-137 (2008).
45. Collins S, Surwit RS. Pharmacologic manipulation of ob expression in a dietary model of obesity. J. Biol. Chem. 271(16), 9437-9440 (1996). (Pubitemid 26137352)
46. Li X, Grundy SM, Patel SB. Obesity in db and ob animals leads to impaired hepatic very low density lipoprotein secretion and differential secretion of apolipoprotein B-48 and B-100. J. Lipid Res. 38(7), 1277-1288 (1997). (Pubitemid 27332556)
47. Akagiri S, Naito Y, Ichikawa H et al. A mouse model of metabolic syndrome; increase in visceral adipose tissue precedes the development of fatty liver and insulin resistance in high-fat diet-fed male KK/Ta mice. J. Clin. Biochem. Nutr. 42(2), 150-157 (2008). (Pubitemid 351912434)
48. Kobayashi K, Forte TM, Taniguchi S, Ishida BY, Oka K, Chan L. The db/db mouse, a model for diabetic dyslipidemia: Molecular characterization and effects of Western diet feeding. Metabolism 49(1), 22-31 (2000). (Pubitemid 30054029)
49. Strauss V, Wiemer J, Leibold E et al. Influence of strain and sex on the metabolic profile of rats in repeated dose toxicological studies. Toxicol. Lett. 191(1), 88-95 (2009).
50. Clause BT. The Wistar rat as a right choice: Establishing mammalian standards and the ideal of a standardized mammal. J. Hist. Biol. 26(2), 329-349 (1993).
51. Kurtz TW, Morris RC, Pershadsingh HA. The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 13(6 Pt 2), 896-901 (1989). (Pubitemid 19157987)
52. Cusin I, Rohner-Jeanrenaud F, Stricker-Krongrad A, Jeanrenaud B. The weight-reducing effect of an intracerebroventricular bolus injection of leptin in genetically obese fa/fa rats. Reduced sensitivity compared with lean animals. Diabetes 45(10), 1446-1450 (1996). (Pubitemid 26332912)
53. Li S, Zhang HY, Hu CC et al. Assessment of diet-induced obese rats as an obesity model by comparative functional genomics. Obesity (Silver Spring) 16(4), 811-818 (2008). (Pubitemid 351465637)